Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:LNTH

Lantheus Q2 2026 Earnings Report

Lantheus logo
$99.97 -0.03 (-0.03%)
Closing price 04:00 PM Eastern
Extended Trading
$99.97 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Lantheus EPS Results

Actual EPS
$1.55
Consensus EPS
$1.30
Beat/Miss
Beat by +$0.25
One Year Ago EPS
$1.57

Lantheus Revenue Results

Actual Revenue
$388.18 million
Expected Revenue
$363.23 million
Beat/Miss
Beat by +$24.95 million
YoY Revenue Growth
+2.70%

Lantheus Announcement Details

Quarter
Q2 2026
Date
8/6/2026
Time
Before Market Opens
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
9:30AM ET

Upcoming Earnings

Lantheus' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Lantheus' Q2 2026 Press ReleasePress Release
(8-K)
Lantheus' Q2 2026 Quarterly reportQuarterly report
(10-Q)

Lantheus Earnings Headlines

3 Reasons LNTH is Risky and 1 Stock to Buy Instead
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/3-reasons-lnth-risky-1-135702338.html
Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs
September 22 at 4:33 PM  |  marketscreener.comM
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
September 23 at 1:00 AM  |  Chaikin Analytics (Ad)
FDA Approves Lantheus' Bravnetsa As Equivalent To Lutathera For Neuroendocrine Tumors
September 22 at 11:33 AM  |  rttnews.comhttps://www.rttnews.com/3692922/fda-approves-lantheus-bravnetsa-as-equivalent-to-lutathera-for-neuroendocrine-tumors.aspx
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically ...
September 22 at 11:33 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lantheus-receives-final-fda-approval-120000278.html
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
September 22 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366274/0/en/lantheus-receives-final-fda-approval-for-bravnetsa-lutetium-lu-177-dotatate-the-only-radiopharmaceutical-fda-has-determined-to-be-bioequivalent-and-therapeutically-equivalent-to-lu.html
See More Lantheus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantheus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantheus and other key companies, straight to your email.

About Lantheus

Lantheus (NASDAQ:LNTH) (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic imaging agents and radiopharmaceuticals. Its products are designed to help physicians detect, characterize and monitor disease, with applications in cardiology, oncology and other areas of medicine.

The company’s principal products include DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound images, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and assess prostate cancer. Lantheus also offers other imaging products and technologies, including agents used in nuclear medicine and targeted radiopharmaceutical development programs.

Lantheus traces its roots to 1956 and is headquartered in North Billerica, Massachusetts. The company serves healthcare providers and patients through commercial operations in the United States and selected international markets. Brian A. Markison serves as Lantheus’ president and chief executive officer.

View Lantheus Profile
Earnings Tools